Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vulnerability of the locus coeruleus-entorhinal cortex white matter tract in autosomal dominant Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Clinical and biological relevance of objectively-defined subtle cognitive decline in Alzheimer's disease: a narrative review of neuroimaging, biomarker, and clinical progression studies.

The journal of prevention of Alzheimer's disease·2026
Same author

Sex differences in diffusion-weighted imaging outcomes in autosomal dominant Alzheimer's disease.

Brain communications·2026
Same author

Web-based LAS-FNAME and blood biomarkers in autosomal dominant Alzheimer's disease.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Long-term forgetting, sleep, and tau in autosomal-dominant Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Contribution of local amyloid-β and tau burden to hypometabolism in autosomal-dominant Alzheimer's disease.

Brain communications·2026
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Vincent Malotaux1,2, David Fernando Aguillón Niño3, Isabela Gonzalez1

  • 1Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

The APOE3-Christchurch variant may protect against Alzheimer's disease by altering brain structure. Heterozygous carriers show increased cortical thickness in frontal and parietal regions, potentially enhancing cognitive reserve and delaying disease onset.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroimaging
  • Genetics
  • Alzheimer's Disease Research

Background:

  • The APOE3-Christchurch (APOE3Ch) variant is associated with protection against Alzheimer's disease (AD).
  • Understanding the mechanisms of AD resistance is crucial for developing effective interventions.
  • Structural neuroimaging can reveal early brain changes related to AD resistance.

Purpose of the Study:

  • To investigate early structural brain differences in middle-aged heterozygous APOE3Ch carriers compared to non-carriers.
  • To analyze cortical thickness (CT) patterns in relation to AD risk and protective factors.

Main Methods:

  • Structural MRI scans were acquired from 52 non-demented individuals (15 APOE3Ch carriers, 37 non-carriers).
  • Voxel-based morphometry and FreeSurfer analyses were used to assess cortical thickness across 68 regions of interest.
  • Clinical measures including Mini-Mental State Exam (MMSE) and Functional Assessment Staging Tool (FAST) scores were collected.

Main Results:

  • APOE3Ch carriers exhibited increased CT in frontal and parietal regions, and reduced CT in occipital and temporal regions.
  • No significant differences in MMSE or FAST scores were observed between carriers and non-carriers.
  • Cortical thickness in an AD-related meta-region of interest was comparable between groups.

Conclusions:

  • Heterozygous APOE3Ch carriers display distinct early cortical thickness patterns, with greater thickness in fronto-parietal areas.
  • These fronto-parietal changes may contribute to enhanced cognitive reserve, potentially delaying AD onset.
  • Structural brain differences in APOE3Ch carriers may underlie their observed resistance to Alzheimer's disease.